Pivotal Bio Venture Partners Investment Advisor LLC Vaxcyte, Inc. Transaction History
Pivotal Bio Venture Partners Investment Advisor LLC
- $127 Million
- Q3 2024
A detailed history of Pivotal Bio Venture Partners Investment Advisor LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Pivotal Bio Venture Partners Investment Advisor LLC holds 639,539 shares of PCVX stock, worth $55 Million. This represents 57.56% of its overall portfolio holdings.
Number of Shares
639,539
Previous 793,036
19.36%
Holding current value
$55 Million
Previous $59.9 Million
21.93%
% of portfolio
57.56%
Previous 53.95%
Shares
8 transactions
Others Institutions Holding PCVX
# of Institutions
352Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$983 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$939 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$854 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$747 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$421 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.1B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...